Bioresorbable scaffold - A magic bullet for the treatment of coronary artery disease?
Today, drug-eluting metal stents are considered the gold standard for interventional treatment of coronary artery disease. While providing inhibition of neointimal hyperplasia, drug-eluting metal stents have many limitations such as the risk of late and very late stent thrombosis, restriction of vascular vasomotion and chronic local inflammatory reaction due to permanent implantation of a 'metallic cage', recognized as a foreign body. Bioresorbable scaffold stents (BRS) are a new solution, which is trying to overcome the limitation of the 'metallic cage'. This structure provides short-term scaffolding of the vessel and then disappears, leaving nothing behind. The purpose of this review is to present the theoretical rationale for the use of BRS and to outline the clinical outcomes associated with their use in terms of data obtained from RCTs, clinical trials, registries and real life use. We have also tried to answer all questions on this intervention based on available data, with a focus on ABSORB BVS (Abbott Vascular, Santa Clara, USA). We consider that this new technology can be the "magic bullet" to treat coronary artery disease.
Institute for Cardiovascular Medicine Timisoara, Cardiology Department, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Daniel
D
Brie
School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK.
Peter
P
Penson
Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Functional Sciences, Discipline of Pathophysiology, "Victor Babes" University of Medicine and Pharmacy, Timisoara, Romania.
Maria-Corina
MC
Serban
The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease, Baltimore, MA, USA; Preventive Cardiology, CGH Medical Center, Sterling, IL, USA.
Peter P
PP
Toth
Abbott Vascular, Santa Clara, CA, USA.
Charles
C
Simonton
International Centre for Cardiovascular Health, Imperial College, London, UK.
Patrick W
PW
Serruys
Department of Hypertension, Chair of Nephrology and Hypertension, Medical University of Lodz, Lodz, Poland. Electronic address: maciejbanach@aol.co.uk.
Maciej
M
Banach
D020341:Absorbable Implants; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000628:therapy*; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000295:instrumentation*; D011474:Prosthesis Design; D016032:Randomized Controlled Trials as Topic; D015607:Stents; D016896:Treatment Outcome
Atherosclerosis; Bioresorbable stents; Coronary artery disease; Drug-eluting stents